Evidence map›Paper›PMID 34503962›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022

Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After

Matthew M Cousins, Theresa P Devasia, Christopher M Maurino, Justin Mikell, Matthew J Schipper, Ravi K Kaza, Theodore S Lawrence, Kyle C Cuneo, Yuni K Dewaraja

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. A Phase II Study of Optimized Individualized Adaptive Radiotherapy for Hepatocellular Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Matthew M CousinsDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; and.
Theresa P DevasiaDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; and.
Christopher M MaurinoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; and.
Justin MikellDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; and.
Matthew J SchipperDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; and.
Ravi K KazaDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.
Theodore S LawrenceDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; and.
Kyle C CuneoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; and kcuneo@med.umich.edu.
Yuni K DewarajaDepartment of Radiology, University of Michigan, Ann Arbor, Michigan.
University of Michigan–Ann Arbor · USMichigan United · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI THEODORE S LAWRENCE · 1988 to 2026
$178.2M
Imaging and Dosimetry of Yttrium-90 for Personalized Cancer TreatmentR01EB022075 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DEWARAJA, YUNI K · 2016 to 2023
$4.7M
NCI NIH HHS P30 CA046592NIBIB NIH HHS R01 EB022075
6 · The paper itself

Abstract

Liver function may be negatively affected by radiation for treatment of hepatic malignancy. Pretreatment blood cytokine levels are biomarkers for prediction of toxicity and survival after external-beam radiation therapy. We hypothesized that cytokines may also predict outcomes after radioembolization, enabling a biomarker-driven personalized approach to treatment.

Indexed as

Carcinoma, HepatocellularChemical and Drug Induced Liver InjuryEmbolization, TherapeuticLiver NeoplasmsBiomarkersHepatocyte Growth FactorHumansPositron Emission Tomography Computed TomographyProspective StudiesReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type IYttrium RadioisotopesBiomarkersHepatocyte Growth FactorHGF protein, humanReceptors, Tumor Necrosis FactorReceptors, Tumor Necrosis Factor, Type ITNFRSF1A protein, humanYttrium Radioisotopescytokinesinflammationlivertoxicity

Identifiers

PMID34503962
PMCPMC9157720
OpenAlexW3197877879

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.